Skip to main content
Clinical Trials/CTIS2024-514870-29-00
CTIS2024-514870-29-00
Active, not recruiting
Phase 1

A phase I/II study evaluating safety and efficacy of autologous hematopoietic stem and progenitor cells genetically modified with IDUA lentiviral vector encoding for the human a-L-iduronidase gene for the treatment of patients affected by Mucopolysaccharidosis Type I, Hurler variant

Ospedale San Raffaele S.r.l.0 sites8 target enrollmentJune 11, 2024

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Mucopolysaccharidosis type I Hurler
Sponsor
Ospedale San Raffaele S.r.l.
Enrollment
8
Status
Active, not recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 11, 2024
End Date
TBD
Last Updated
last year
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
Ospedale San Raffaele S.r.l.

Eligibility Criteria

Inclusion Criteria

  • Written informed consent by parent/legal guardian, Sex: Males or Females, Age: \= 28 days and \= 11 years old, Biochemically and molecularly proven MPS IH, Lansky Index \> 80 %, Indication to HSCT, Lack of a non\-heterozygous (for mutated IDUA) HLA\-matched sibling donor or a \=7/8 (4 digits high\-resolution typing) HLA\-matched cord blood donor with a cellularity \=5 x 107 Total Nucleated Cells (TNC)/Kg after 1\-month search. This criterion will not apply to patients whose country of origin does not offer unrelated donor cord blood transplantation., Adequate cardiac, renal, hepatic and pulmonary functions

Exclusion Criteria

  • Use of other investigational agents within 4 weeks prior to study enrolment (within 6 weeks if use of long\-acting agents), Controindications to PeIMP (G\-CSF, Plerixafor, Busulfan, Fludarabine, Rituximab), Severe, active viral, bacterial, or fungal infection at eligibility evaluation, Patients affected by malignant neoplasia or family history of familial cancer syndromes, Cytogenetic alterations associated with high risk of developing hematological malignancies, History of uncontrolled seizures, Patients with end\-organ damage or any other severe disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study, Positivity for HIV (serology or RNA), and/or HbsAg and/or HBV DNA and/or HCV RNA and/or Treponema Pallidum or Mycoplasma active infection, Patients with DQ/IQ \<70 (Cognitive Scale for Bayley Scale of Infant Development and Performance IQ for wppsi and wisc), Previous allogeneic HSCT or gene therapy with a different product

Outcomes

Primary Outcomes

Not specified

Similar Trials